228 related articles for article (PubMed ID: 35806291)
1. Targeting the SREBP-1/Hsa-Mir-497/SCAP/FASN Oncometabolic Axis Inhibits the Cancer Stem-like and Chemoresistant Phenotype of Non-Small Cell Lung Carcinoma Cells.
Tiong TY; Weng PW; Wang CH; Setiawan SA; Yadav VK; Pikatan NW; Fong IH; Yeh CT; Hsu CH; Kuo KT
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806291
[TBL] [Abstract][Full Text] [Related]
2. LINC00852 is associated with poor prognosis in non-small cell lung cancer patients and its inhibition suppresses cancer cell proliferation and chemoresistance via the hsa-miR-145-5p/KLF4 axis.
Tuo Z; Liang L; Zhou R
J Gene Med; 2021 Dec; 23(12):e3384. PubMed ID: 34342374
[TBL] [Abstract][Full Text] [Related]
3. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
4. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1.
Ma Z; Cai H; Zhang Y; Chang L; Cui Y
Biochem Biophys Res Commun; 2017 Aug; 490(2):309-316. PubMed ID: 28619508
[TBL] [Abstract][Full Text] [Related]
5. Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis.
Zheng S; Wang C; Yan H; Du Y
Bioengineered; 2021 Dec; 12(1):8347-8357. PubMed ID: 34592879
[TBL] [Abstract][Full Text] [Related]
6. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
7. Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
Huang LH; Chung HY; Su HM
BMC Cancer; 2017 Dec; 17(1):890. PubMed ID: 29282029
[TBL] [Abstract][Full Text] [Related]
8. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
9. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
10. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
12. Circular RNA hsa_circ_0014130 Inhibits Apoptosis in Non-Small Cell Lung Cancer by Sponging miR-136-5p and Upregulating BCL2.
Geng Y; Bao Y; Zhang W; Deng L; Su D; Zheng H
Mol Cancer Res; 2020 May; 18(5):748-756. PubMed ID: 32060230
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate inhibited cancer stem cell-like properties by targeting hsa-mir-485-5p/RXRα in lung cancer.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
J Cell Biochem; 2018 Nov; 119(10):8623-8635. PubMed ID: 30058740
[TBL] [Abstract][Full Text] [Related]
14. LncRNA DGCR5 contributes to CSC-like properties via modulating miR-330-5p/CD44 in NSCLC.
Wang R; Dong HX; Zeng J; Pan J; Jin XY
J Cell Physiol; 2018 Sep; 233(9):7447-7456. PubMed ID: 29663359
[TBL] [Abstract][Full Text] [Related]
15. Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer.
Jin X; Guan Y; Zhang Z; Wang H
BMC Cancer; 2020 Apr; 20(1):329. PubMed ID: 32299382
[TBL] [Abstract][Full Text] [Related]
16. Soy isoflavone genistein inhibits hsa_circ_0031250/miR-873-5p/FOXM1 axis to suppress non-small-cell lung cancer progression.
Yu Y; Xing Y; Zhang Q; Zhang Q; Huang S; Li X; Gao C
IUBMB Life; 2021 Jan; 73(1):92-107. PubMed ID: 33159503
[TBL] [Abstract][Full Text] [Related]
17. TNFAIP2 Promotes Non-Small Cell Lung Cancer Cells and Targeted by miR-145-5p.
Li J; Song Y; Yu B; Yu Y
DNA Cell Biol; 2020 Jul; 39(7):1256-1263. PubMed ID: 32456459
[TBL] [Abstract][Full Text] [Related]
18. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
Xie H; Yao J; Wang Y; Ni B
Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
[TBL] [Abstract][Full Text] [Related]
19. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
20. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
